Entir is just one of the most famously recommended antiviral drugs. It is used to decrease the development of the herpes pc virus permitting your physical body and the invulnerable system to fight off the infection. Entir is planned for patients identified with genital herpes, cold sores, roof shingles, and poultry pox. You need to take this medication for the entire length of time advised by your doctor, trying not to miss amounts and take Entir at normal periods. It's best to start the therapy as early as you notice the first signs of the infection, such as burning, tingling or blisters. Entir is not expected to affect the wellness of a coming infant, it can pass in to bust milk. Inform your physician regarding maternity or breastfeeding prior to starting to take Entir.
Why is this medication prescribed?
Entir is used to decrease pain and speed the healing of sores or blisters in people who have varicella (chickenpox), herpes zoster (shingles; a rash that can occur in people who have had chickenpox in the past), and first-time or repeat outbreaks of genital herpes (a herpes virus infection that causes sores to form around the genitals and rectum from time to time). Entir is also sometimes used to prevent outbreaks of genital herpes in people who are infected with the virus. Entir is in a class of antiviral medications called synthetic nucleoside analogues. It works by stopping the spread of the herpes virus in the body. Entir will not cure genital herpes and may not stop the spread of genital herpes to other people.
Q: Does Entir cause hair loss?
A: During post marketing experience, observed in clinical practice, Entir (Zovirax) was reported to cause hair loss. However, because adverse reactions reported in clinical practice, and not during controlled clinical trials, are reported voluntarily from an unknown population size, the frequency of the adverse reaction is unknown. Other adverse reactions reported during post marketing experience with Entir included headache, allergic reaction, fever, pain, swelling in the extremities, agitation, confusion, dizziness, somnolence, tremors, diarrhea, gastrointestinal distress, nausea, anemia, leucopenia, thrombocytopenia, elevated liver enzymes, hepatitis, jaundice, myalgia, prutitus, rash, visual disturbances, kidney failure, kidney pain, elevated blood urea nitrogen (BUN) and creatinine, and hematuria. According to the prescribing information for Zovirax, the brand-name of Entir, the most frequently reported adverse reactions reported during clinical trials included nausea, vomiting, diarrhea, malaise and headache and varied depending on the indication for treatment. Patients are instructed to contact their health care provider, immediately, if they experience symptoms which may indicate more serious adverse reactions of Entir have developed. Symptoms may include pain the lower back, urinating less than usual or not urinating at all, easy bruising or bleeding, and unusual weakness. It is important for patients to report any unusual or bothersome reactions they experience while being treated with Entir. Entir should be taken exactly as prescribed.
- Take this drug at the time(s) recommended by your doctor.
- You can take Entir with or without food. Taking it with food may help reduce upset stomach.
- Do not cut or crush this medication.
- Not every pharmacy stocks this drug. When filling your prescription, be sure to call ahead to make sure your pharmacy carries it.
- The dosage of ZOVIRAX® (Entir) should be reduced in patients with impaired renal function.
- Therapy should be initiated as soon as possible after a diagnosis of chickenpox or herpes zoster, or at the first sign or symptoms of an outbreak of genital herpes.
- The recommended dose and duration of use is dependent on the indication.
Entir was shown not to impair fertility or reproduction in groups of 15 male and 30 female mice in a two-generation fertility study. The mice in this study were given Entir by gastric intubation at dosage levels of 50, 150 and 450 mg/kg/day. Males were dosed for 64 consecutive days prior to mating and females for 21 days prior to mating.
In a rat fertility study where groups of 20 male and 20 female rats were given 0, 12.5, 25.0 and 50.0 mg/kg/day by subcutaneous injection, Entir was shown not to have an effect on mating or fertility. The males were dosed for 60 days prior to mating and until their mating schedule was completed. Female rats were dosed for 14 days prior to mating and until day 7 of pregnancy. At 50 mg/kg/day s.c. there was a statistically significant increase in post-implantation loss, but no concomitant decrease in litter size.
In 25 female rabbits treated subcutaneously with 50 mg/kg/day Entir on days 6 to 18 of gestation, there was a statistically significant decrease in implantation efficiency but no concomitant decrease in litter size. There was also a dose-related increase in the number of fetuses with supernumerary ribs in all drug-treated groups. This increase was not dose-related when the incidence of supernumerary ribs per litter was examined.
In 15 female rabbits treated intravenously with 50 mg/kg/day Entir on days 6 to 18 of gestation, there was no effect on either implantation efficiency or litter size.
In a rat peri- and postnatal study (20 female rats per group), Entir was given subcutaneously at 0, 12.5, 25 and 50 mg/kg/day from 17 days of gestation to 21 days postpartum. At 50 mg/kg/day s.c. there was a statistically significant decrease in the group mean numbers of corpora lutea, total implantation sites and live fetuses in the F1 generation. Although not statistically significant, there was also a dose-related decrease in group mean numbers of live fetuses and implantation sites at 12.5 mg/kg/day and 25 mg/kg/day s.c.
In a dose-range finding study with 5 female rabbits the intravenous administration of Entir at a dose of 100 mg/kg/day from days 6 to 8 of pregnancy, a dose known to cause obstructive nephropathy, caused a significant increase in fetal resorptions and a corresponding decrease in litter size. At a maximum tolerated intravenous dose of 50 mg/kg/day in rabbits there were no drug-related reproductive effects.
In a subchronic toxicity study where groups of 20 male and 20 female rats were given intraperitoneal doses of Entir at 0, 20, 80 or 320 mg/kg/day for one month, and followed for a one-month postdose period, there was testicular atrophy. Some histologic evidence of recovery of sperm production was evident 30 days postdose, but this was insufficient time to demonstrate full reversibility.
Groups of 25 male and 25 female rats were administered intraperitoneal doses of Entir at 0, 5, 20 or 80 mg/kg/day for 6 months. Ten male and 10 female rats in each group were continued undosed for 13 weeks. Testicular atrophy was limited to high-dose rats given 80 mg/kg/day for 6 months. Organ weight data and light microscopy defined full reversibility of the testicular atrophy by the end of the postdose recovery period.
In a 31-day dog study (16 males and 16 females per group) where Entir was administered intravenously at levels of 50, 100 and 200 mg/kg/day, testicles were normal in dogs at 50 mg/kg. Doses of 100 or 200 mg/kg/day caused death of some dogs due to cytostatic effects (bone marrow and gastrointestinal epithelium) and aspermic testes or testes with scattered aspermic tubules. It cannot be ruled out that the testicular change may have been primary, however, similar changes can be observed secondary to severe stress in moribund dogs.
To use buccal Entir, follow these steps:
- Find the area on the upper gum above your left and right incisor teeth (the teeth just to the left and right of your two front teeth).
- With dry hands, remove one delayed-release tablet from the container.
- Gently apply the tablet to the upper gum area as high as it will go on your gum above one of your incisor teeth on the side of your mouth with the cold sore. Do not apply it to the inside of the lip or cheek.
- Hold the tablet in place for 30 seconds.
- If the tablet does not stick to your gum or if it sticks to your cheek or the inside of your lip, reposition it to stick to your gum. Leave the tablet in place until it dissolves.
- Do not interfere with the placement of the tablet. Check to see if the tablet is still in place after eating, drinking, or rinsing your mouth.
If the delayed-release buccal tablet comes off within the first 6 hours of application, reapply the same tablet. If it still will not stick, then apply a new tablet. If you accidentally swallow the tablet within the first 6 hours of application, drink a glass of water and place a new tablet on your gum. If the tablet falls off or is swallowed 6 or more hours after application, do not apply a new tablet until your next regular time.
Before taking this medicine
You should not take this medicine if you are allergic to Entir or valEntir (Valtrex). You should not take Entir buccal tablets (Sitavig) if you are allergic to milk proteins.
To make sure Entir is safe for you, tell your doctor if you have:
kidney disease; or
a weak immune system (caused by disease or by using certain medicine).
Entir is not expected to harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment.
Herpes can be passed to your baby during childbirth if you have a genital lesion when your baby is born. If you have genital herpes, it is very important to prevent herpes lesions during pregnancy. Take your medicine as directed to best control your infection.
Entir passes into breast milk, but is considered compatible with breast feeding. Tell your doctor if you are breast-feeding a baby while taking this medication.
Use in younger children is not recommended due to potential risk of choking.